JP6639497B2 - ブロモドメインインヒビターおよびその使用 - Google Patents
ブロモドメインインヒビターおよびその使用 Download PDFInfo
- Publication number
- JP6639497B2 JP6639497B2 JP2017525079A JP2017525079A JP6639497B2 JP 6639497 B2 JP6639497 B2 JP 6639497B2 JP 2017525079 A JP2017525079 A JP 2017525079A JP 2017525079 A JP2017525079 A JP 2017525079A JP 6639497 B2 JP6639497 B2 JP 6639497B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocyclyl
- carbocyclyl
- oxo
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C[C@](**)C(N(C)CC1CCN(C)CC1)=O Chemical compound C[C@](**)C(N(C)CC1CCN(C)CC1)=O 0.000 description 44
- ZXCJNVPJXFEXMJ-NSCUHMNNSA-N C/C=C/CN(C=C(C(NCc1ccccc1)=O)c1c2[nH]cc1)C2=O Chemical compound C/C=C/CN(C=C(C(NCc1ccccc1)=O)c1c2[nH]cc1)C2=O ZXCJNVPJXFEXMJ-NSCUHMNNSA-N 0.000 description 1
- LUCLJGBDSYDVPO-UHFFFAOYSA-N C/S=C/C(N(CC1)CCC1C1=CC(F)=CC#CC1)=O Chemical compound C/S=C/C(N(CC1)CCC1C1=CC(F)=CC#CC1)=O LUCLJGBDSYDVPO-UHFFFAOYSA-N 0.000 description 1
- LSANJNKSAFQJBZ-UHFFFAOYSA-N CC(C)(C)OC(NC(CC1)CCN1c1ccccc1)=O Chemical compound CC(C)(C)OC(NC(CC1)CCN1c1ccccc1)=O LSANJNKSAFQJBZ-UHFFFAOYSA-N 0.000 description 1
- SHRPIRGIQGLOIS-UHFFFAOYSA-N CC(C)CN(CC1)CCC1N(C)C=O Chemical compound CC(C)CN(CC1)CCC1N(C)C=O SHRPIRGIQGLOIS-UHFFFAOYSA-N 0.000 description 1
- WNAIVABIHSZWPD-UHFFFAOYSA-N CC(C)N1CCC(CCNC)CC1 Chemical compound CC(C)N1CCC(CCNC)CC1 WNAIVABIHSZWPD-UHFFFAOYSA-N 0.000 description 1
- ZHZUVBBBOHNVIT-UHFFFAOYSA-N CC(C)N1CCC2(CC2)CC1 Chemical compound CC(C)N1CCC2(CC2)CC1 ZHZUVBBBOHNVIT-UHFFFAOYSA-N 0.000 description 1
- VWVDYFBWPFYGNZ-UHFFFAOYSA-N CC(CN(CC1)CCC1NC)c1ccccc1 Chemical compound CC(CN(CC1)CCC1NC)c1ccccc1 VWVDYFBWPFYGNZ-UHFFFAOYSA-N 0.000 description 1
- JAKDWKVKEBOKAO-UHFFFAOYSA-N CC(N(CC1)CCC1C1=NCCC=C1)=O Chemical compound CC(N(CC1)CCC1C1=NCCC=C1)=O JAKDWKVKEBOKAO-UHFFFAOYSA-N 0.000 description 1
- ADKJRMANIGACDE-UHFFFAOYSA-N CC(N(CC1)CCC1[n]1c(cccc2)c2nc1)=O Chemical compound CC(N(CC1)CCC1[n]1c(cccc2)c2nc1)=O ADKJRMANIGACDE-UHFFFAOYSA-N 0.000 description 1
- LLXZOVPVHKQYES-SJCNYWDSSA-N CC/C=N\C(\C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O)=C/N Chemical compound CC/C=N\C(\C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O)=C/N LLXZOVPVHKQYES-SJCNYWDSSA-N 0.000 description 1
- DGAIXSHBZAYDFH-UHFFFAOYSA-N CC1(CNC(C(c2c3[nH]cc2)=CN(C)C3=O)=O)CCN(C)CC1 Chemical compound CC1(CNC(C(c2c3[nH]cc2)=CN(C)C3=O)=O)CCN(C)CC1 DGAIXSHBZAYDFH-UHFFFAOYSA-N 0.000 description 1
- GWFPELGLVGDRGE-UHFFFAOYSA-N CCCC(N(CC1)CC=C1c1nccnc1)=O Chemical compound CCCC(N(CC1)CC=C1c1nccnc1)=O GWFPELGLVGDRGE-UHFFFAOYSA-N 0.000 description 1
- VVXLSXDXEAYQHD-UHFFFAOYSA-N CCCCN(C=C(C(NCc1ccccc1)=O)c1c2[nH]cc1)C2=O Chemical compound CCCCN(C=C(C(NCc1ccccc1)=O)c1c2[nH]cc1)C2=O VVXLSXDXEAYQHD-UHFFFAOYSA-N 0.000 description 1
- QNSMULHHPGYUEK-UHFFFAOYSA-N CCN(C(CC1)CCN1C(C)C)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CCN(C(CC1)CCN1C(C)C)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O QNSMULHHPGYUEK-UHFFFAOYSA-N 0.000 description 1
- CQCGEHBJCMHEAA-UHFFFAOYSA-N CCN1CCC(CCNC)CC1 Chemical compound CCN1CCC(CCNC)CC1 CQCGEHBJCMHEAA-UHFFFAOYSA-N 0.000 description 1
- FBVGIYYPPOCZOL-UHFFFAOYSA-N CCS(C)C(N(C)CC1CCN(CC2COCCC2)CC1)=O Chemical compound CCS(C)C(N(C)CC1CCN(CC2COCCC2)CC1)=O FBVGIYYPPOCZOL-UHFFFAOYSA-N 0.000 description 1
- GKXRDGWOKDGUJK-UHFFFAOYSA-N CN(C(C(c1c2[nH]cc1)=CN(C)C2=O)O)C1CCN(CC2C(Cl)=CC=CC2)CC1 Chemical compound CN(C(C(c1c2[nH]cc1)=CN(C)C2=O)O)C1CCN(CC2C(Cl)=CC=CC2)CC1 GKXRDGWOKDGUJK-UHFFFAOYSA-N 0.000 description 1
- BNKMXMCVPWPRMR-SNAWJCMRSA-N CN(C)/C=C/c(c([N+]([O-])=O)c(nc1)OC)c1Br Chemical compound CN(C)/C=C/c(c([N+]([O-])=O)c(nc1)OC)c1Br BNKMXMCVPWPRMR-SNAWJCMRSA-N 0.000 description 1
- MJAWJIDTMXGSQY-UHFFFAOYSA-N CN(C)C(N(C)CCC(CC1)CCN1C1CCC1)=O Chemical compound CN(C)C(N(C)CCC(CC1)CCN1C1CCC1)=O MJAWJIDTMXGSQY-UHFFFAOYSA-N 0.000 description 1
- RHTIIFADKOEUSR-UHFFFAOYSA-N CN(C)C(N(CC1)CCC1c1ncncc1)=O Chemical compound CN(C)C(N(CC1)CCC1c1ncncc1)=O RHTIIFADKOEUSR-UHFFFAOYSA-N 0.000 description 1
- BWDUSWMVCCCWOD-UHFFFAOYSA-N CN(C1CCCCC1)C(CC1)CCN1C=O Chemical compound CN(C1CCCCC1)C(CC1)CCN1C=O BWDUSWMVCCCWOD-UHFFFAOYSA-N 0.000 description 1
- XFIGPGHJQQOBKW-UHFFFAOYSA-N CN(C1CCN(CC2CCCC2)CC1)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CN(C1CCN(CC2CCCC2)CC1)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O XFIGPGHJQQOBKW-UHFFFAOYSA-N 0.000 description 1
- MROZMKBPOKVBBH-UHFFFAOYSA-N CN(C1CCN(Cc(cc2)ccc2OC)CC1)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CN(C1CCN(Cc(cc2)ccc2OC)CC1)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O MROZMKBPOKVBBH-UHFFFAOYSA-N 0.000 description 1
- LCSHIPRHJNILHL-UHFFFAOYSA-N CN(C1CCN(Cc2cccc(C#N)c2)CC1)C(C(C1C=CNC11)=CN(C)C1=O)=O Chemical compound CN(C1CCN(Cc2cccc(C#N)c2)CC1)C(C(C1C=CNC11)=CN(C)C1=O)=O LCSHIPRHJNILHL-UHFFFAOYSA-N 0.000 description 1
- JRKXRGQEAQFGGL-UHFFFAOYSA-N CN(C=C(C(N(CC1)CC1c1ccccc1)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(N(CC1)CC1c1ccccc1)=O)c1c2[nH]cc1)C2=O JRKXRGQEAQFGGL-UHFFFAOYSA-N 0.000 description 1
- AGBGSLZWJZAUMY-UHFFFAOYSA-N CN(C=C(C(N(CC1)CCC1[n]1c(cccc2)c2nc1)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(N(CC1)CCC1[n]1c(cccc2)c2nc1)=O)c1c2[nH]cc1)C2=O AGBGSLZWJZAUMY-UHFFFAOYSA-N 0.000 description 1
- BHHVAFVZSIJORC-UHFFFAOYSA-N CN(C=C(C(N1Cc(cccc2)c2NCC1)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(N1Cc(cccc2)c2NCC1)=O)c1c2[nH]cc1)C2=O BHHVAFVZSIJORC-UHFFFAOYSA-N 0.000 description 1
- XVXHKGNUMIJBAD-UHFFFAOYSA-N CN(C=C(C(NC(CC1)CCN1C1N=CC(F)=CN1)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(NC(CC1)CCN1C1N=CC(F)=CN1)=O)c1c2[nH]cc1)C2=O XVXHKGNUMIJBAD-UHFFFAOYSA-N 0.000 description 1
- PNALRLFVFGKUKX-UHFFFAOYSA-N CN(C=C(C(NC1C=COC1)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(NC1C=COC1)=O)c1c2[nH]cc1)C2=O PNALRLFVFGKUKX-UHFFFAOYSA-N 0.000 description 1
- QMPDMDGMUAEDHK-UHFFFAOYSA-N CN(C=C(C(NCC(C1)COc2c1cccc2)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(NCC(C1)COc2c1cccc2)=O)c1c2[nH]cc1)C2=O QMPDMDGMUAEDHK-UHFFFAOYSA-N 0.000 description 1
- BEMPMIUBVLGEPQ-UHFFFAOYSA-N CN(C=C(C(NCC1CCCCCC1)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(NCC1CCCCCC1)=O)c1c2[nH]cc1)C2=O BEMPMIUBVLGEPQ-UHFFFAOYSA-N 0.000 description 1
- AGMJKSJGYPGZPB-UHFFFAOYSA-N CN(C=C(C(NCC1COCC1)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(NCC1COCC1)=O)c1c2[nH]cc1)C2=O AGMJKSJGYPGZPB-UHFFFAOYSA-N 0.000 description 1
- FLWIRTWYZJMNBG-UHFFFAOYSA-N CN(C=C(C(NCC1COCCC1)O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(NCC1COCCC1)O)c1c2[nH]cc1)C2=O FLWIRTWYZJMNBG-UHFFFAOYSA-N 0.000 description 1
- GCZQKQBRKSMHAX-UHFFFAOYSA-N CN(C=C(C(NCC1Oc2ccccc2C1)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(NCC1Oc2ccccc2C1)=O)c1c2[nH]cc1)C2=O GCZQKQBRKSMHAX-UHFFFAOYSA-N 0.000 description 1
- JTFBTQHEFKCEPE-UHFFFAOYSA-N CN(C=C(C(NCCc1ccccc1)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(NCCc1ccccc1)=O)c1c2[nH]cc1)C2=O JTFBTQHEFKCEPE-UHFFFAOYSA-N 0.000 description 1
- URFZAUPPMVLKMD-UHFFFAOYSA-N CN(C=C(C(NCc(cc1)ccc1OC)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(NCc(cc1)ccc1OC)=O)c1c2[nH]cc1)C2=O URFZAUPPMVLKMD-UHFFFAOYSA-N 0.000 description 1
- DVRDHMAGVNMCOD-UHFFFAOYSA-N CN(C=C(C(NCc1ccc[s]1)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(NCc1ccc[s]1)=O)c1c2[nH]cc1)C2=O DVRDHMAGVNMCOD-UHFFFAOYSA-N 0.000 description 1
- NUUFHJMMEKQNCY-UHFFFAOYSA-N CN(C=C(C(NCc1ccccc1)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(NCc1ccccc1)=O)c1c2[nH]cc1)C2=O NUUFHJMMEKQNCY-UHFFFAOYSA-N 0.000 description 1
- KIZJICQBENRKQQ-PDKSGFIFSA-N CN(C=C(C(N[C@@H]1C2=CC=CC=CC2C1[C@H](c1ccccc1)O)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(N[C@@H]1C2=CC=CC=CC2C1[C@H](c1ccccc1)O)=O)c1c2[nH]cc1)C2=O KIZJICQBENRKQQ-PDKSGFIFSA-N 0.000 description 1
- ZRPSUTWDOPJWPG-UHFFFAOYSA-N CN(CC(C(N(CC1)CCC1c1cc(F)ccc1)=O)c1c2[nH]cc1)C2=O Chemical compound CN(CC(C(N(CC1)CCC1c1cc(F)ccc1)=O)c1c2[nH]cc1)C2=O ZRPSUTWDOPJWPG-UHFFFAOYSA-N 0.000 description 1
- USMTZDXXYMQBNJ-UHFFFAOYSA-N CN(CC(CC1)CCN1C1CC1)C=O Chemical compound CN(CC(CC1)CCN1C1CC1)C=O USMTZDXXYMQBNJ-UHFFFAOYSA-N 0.000 description 1
- ICPGUFVUGUANLR-UHFFFAOYSA-N CN(CC1CCN(CCOC)CC1)C(N)=O Chemical compound CN(CC1CCN(CCOC)CC1)C(N)=O ICPGUFVUGUANLR-UHFFFAOYSA-N 0.000 description 1
- MSYKRJYFLDVFEC-UHFFFAOYSA-N CN(CCC1CCN(C)CC1)C=O Chemical compound CN(CCC1CCN(C)CC1)C=O MSYKRJYFLDVFEC-UHFFFAOYSA-N 0.000 description 1
- NAYVEAARSMTFNB-AUPPTIGGSA-N CN(CO)C(CC1)CCN1C(C1)C1/N=C(/C(F)(F)F)\C=C/N Chemical compound CN(CO)C(CC1)CCN1C(C1)C1/N=C(/C(F)(F)F)\C=C/N NAYVEAARSMTFNB-AUPPTIGGSA-N 0.000 description 1
- XJBZDCYCDWDAQH-UHFFFAOYSA-N CN(Cc1ccccc1)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CN(Cc1ccccc1)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O XJBZDCYCDWDAQH-UHFFFAOYSA-N 0.000 description 1
- PAAZMWQUHZPENI-JYAVWHMHSA-N CN([C@@H]1[C@@H]2[C@H]1CNC2)C(C(c1c2[nH]cc1)=CN(CC=C)C2=O)=O Chemical compound CN([C@@H]1[C@@H]2[C@H]1CNC2)C(C(c1c2[nH]cc1)=CN(CC=C)C2=O)=O PAAZMWQUHZPENI-JYAVWHMHSA-N 0.000 description 1
- ZORBHPKWEBTNPG-UHFFFAOYSA-N CNC(CC1)CCN1c1cnccn1 Chemical compound CNC(CC1)CCN1c1cnccn1 ZORBHPKWEBTNPG-UHFFFAOYSA-N 0.000 description 1
- URBRWYHLJDZHDG-UHFFFAOYSA-N CNCCC1CCN(CCOC)CC1 Chemical compound CNCCC1CCN(CCOC)CC1 URBRWYHLJDZHDG-UHFFFAOYSA-N 0.000 description 1
- YRVHFGOAEVWBNS-UHFFFAOYSA-N COc(ncc(Br)c1)c1[N+]([O-])=O Chemical compound COc(ncc(Br)c1)c1[N+]([O-])=O YRVHFGOAEVWBNS-UHFFFAOYSA-N 0.000 description 1
- FFQGWHSSQOZSHS-LLVKDONJSA-N C[C@H](c1ccccc1)NC(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound C[C@H](c1ccccc1)NC(C(c1c2[nH]cc1)=CN(C)C2=O)=O FFQGWHSSQOZSHS-LLVKDONJSA-N 0.000 description 1
- WGQLKTURHHFDKT-UHFFFAOYSA-N Cc1cc(C(C(N(C)C(CC2)CCN2c2cc(C3C(C)=NC=CC3)ncn2)=O)=CN(CC=C)C2=O)c2[nH]1 Chemical compound Cc1cc(C(C(N(C)C(CC2)CCN2c2cc(C3C(C)=NC=CC3)ncn2)=O)=CN(CC=C)C2=O)c2[nH]1 WGQLKTURHHFDKT-UHFFFAOYSA-N 0.000 description 1
- OZOIEFPQQQDUHM-UHFFFAOYSA-N Cc1ccc(CN(CC2)CCC2N(C)C(C(C2C=CNC22)=CN(C)C2=O)=O)cc1 Chemical compound Cc1ccc(CN(CC2)CCC2N(C)C(C(C2C=CNC22)=CN(C)C2=O)=O)cc1 OZOIEFPQQQDUHM-UHFFFAOYSA-N 0.000 description 1
- INBAALZXDRSEDW-UHFFFAOYSA-N Cc1ccccc1CN1CCC(CN(C)C=O)CC1 Chemical compound Cc1ccccc1CN1CCC(CN(C)C=O)CC1 INBAALZXDRSEDW-UHFFFAOYSA-N 0.000 description 1
- XCZPUYLNUVNESP-UHFFFAOYSA-N Cc1ccnc(N(CC2)CCC2NC)n1 Chemical compound Cc1ccnc(N(CC2)CCC2NC)n1 XCZPUYLNUVNESP-UHFFFAOYSA-N 0.000 description 1
- FHXKOHRPZOJNSQ-UHFFFAOYSA-N O=CN(CC1)CCC1c(cc1)ccc1Cl Chemical compound O=CN(CC1)CCC1c(cc1)ccc1Cl FHXKOHRPZOJNSQ-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N OC(C(F)(F)F)=O Chemical compound OC(C(F)(F)F)=O DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077711P | 2014-11-10 | 2014-11-10 | |
| US62/077,711 | 2014-11-10 | ||
| PCT/US2015/059997 WO2016077375A1 (en) | 2014-11-10 | 2015-11-10 | Bromodomain inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533250A JP2017533250A (ja) | 2017-11-09 |
| JP2017533250A5 JP2017533250A5 (https=) | 2018-12-20 |
| JP6639497B2 true JP6639497B2 (ja) | 2020-02-05 |
Family
ID=54705827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525079A Expired - Fee Related JP6639497B2 (ja) | 2014-11-10 | 2015-11-10 | ブロモドメインインヒビターおよびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10258603B2 (https=) |
| EP (1) | EP3218376B1 (https=) |
| JP (1) | JP6639497B2 (https=) |
| CN (1) | CN107108613B (https=) |
| WO (1) | WO2016077375A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840489B2 (en) | 2013-12-20 | 2017-12-12 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | Piperidine carboxamide compound, preparation method, and usage thereof |
| WO2016077375A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Bromodomain inhibitors and uses thereof |
| MA40943A (fr) * | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| EP3250571B1 (en) | 2015-01-29 | 2022-11-30 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| EP3445357B1 (en) | 2016-04-22 | 2021-05-26 | Dana-Farber Cancer Institute, Inc. | Bifunctional molecules for degradation of egfr and methods of use |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| CN110198941B (zh) * | 2017-01-25 | 2021-09-28 | 江苏豪森药业集团有限公司 | 吡咯并吡啶类n-氧化衍生物及其制备方法和应用 |
| WO2019201291A1 (zh) * | 2018-04-20 | 2019-10-24 | 中国科学院上海药物研究所 | 组蛋白乙酰转移酶(hat)抑制剂及其用途 |
| KR20210038911A (ko) * | 2018-07-24 | 2021-04-08 | 에피자임, 인코포레이티드 | Smarca2 길항제로서 유용한 피리딘-2-온 화합물 |
| CN114008049B (zh) * | 2019-06-21 | 2024-07-05 | 豪夫迈·罗氏有限公司 | 用于癌症治疗的egfr抑制剂 |
| US11171132B2 (en) * | 2019-10-03 | 2021-11-09 | Globalfoundries U.S. Inc. | Bi-directional breakdown silicon controlled rectifiers |
| CN112625036A (zh) * | 2019-10-08 | 2021-04-09 | 上海海和药物研究开发股份有限公司 | 一类具有brd4抑制活性的化合物、其制备方法及用途 |
| AU2021231898A1 (en) | 2020-03-05 | 2022-10-27 | C4 Therapeutics, Inc. | Compounds for targeted degradation of BRD9 |
| WO2022051565A1 (en) * | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds and their use in treating medical conditions |
| CN117377668A (zh) * | 2020-10-15 | 2024-01-09 | 迈欧伏特治疗公司 | Pgdh抑制剂的吸入制剂及其使用方法 |
| TW202237095A (zh) | 2020-12-03 | 2022-10-01 | 德商艾斯巴赫生物有限公司 | Ａｌｃ１抑制劑及與ｐａｒｐｉ之協同性 |
| CA3237258A1 (en) * | 2021-11-03 | 2023-05-11 | Iain Stuart | Uses of pan bet inhibitors |
| JP2025515110A (ja) | 2022-05-02 | 2025-05-13 | アイスバッハ・バイオ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ａｌｃ１阻害剤の使用およびｐａｒｐｉとの相乗作用 |
| CN119384408A (zh) | 2022-06-16 | 2025-01-28 | 安菲斯塔治疗有限责任公司 | 用于靶向蛋白降解的双功能分子 |
| EP4587126A1 (en) | 2022-09-13 | 2025-07-23 | Amphista Therapeutics Ltd | Compounds for targeted protein degradation |
| GB202300833D0 (en) * | 2023-01-19 | 2023-03-08 | Nrg Therapeutics Ltd | Novel compounds |
| TW202523312A (zh) * | 2023-10-16 | 2025-06-16 | 美商克洛諾斯生技有限公司 | 離胺酸乙醯基轉移酶抑制劑 |
| GB202319256D0 (en) | 2023-12-15 | 2024-01-31 | Amphista Therapeutics Ltd | Novel compounds for targeted protein degradation |
| WO2025191109A1 (en) | 2024-03-13 | 2025-09-18 | Amphista Therapeutics Limited | Combinations comprising brd9 bifunctional compounds and their use in the treatment of cancer |
| WO2026052822A1 (en) | 2024-09-06 | 2026-03-12 | Amphista Therapeutics Limited | Tetrahydroisoquinoline compounds for targeted protein degradation |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| EP0659439B1 (en) | 1993-12-24 | 2001-10-24 | MERCK PATENT GmbH | Immunoconjugates |
| US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| PL179659B1 (pl) | 1994-07-21 | 2000-10-31 | Akzo Nobel Nv | Kompozycja cyklicznych nadtlenków ketonów sluzaca do modyfikowania (ko)polimerów zwlaszcza do degradacji polipropylenu PL PL PL PL PL PL PL |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| MX9707453A (es) | 1995-03-30 | 1997-12-31 | Pfizer | Derivados de quinazolina. |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| MX9800215A (es) | 1995-07-06 | 1998-03-31 | Novartis Ag | Pirrolopirimidas y procesos para su preparacion. |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| HU228446B1 (en) | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| ID19609A (id) | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| ATE241986T1 (de) | 1997-05-06 | 2003-06-15 | Wyeth Corp | Verwendung von chinazolin verbindungen zur behandlung von polyzystischer nierenkrankheit |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| CN1278176A (zh) | 1997-11-06 | 2000-12-27 | 美国氰胺公司 | 喹唑啉衍生物作为用于治疗结肠息肉的酪氨酸激酶抑制剂的应用 |
| WO2000031048A1 (en) | 1998-11-19 | 2000-06-02 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| EP1953147A1 (en) | 2005-11-21 | 2008-08-06 | Japan Tobacco, Inc. | Heterocyclic compound and medicinal application thereof |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US20140094456A1 (en) | 2012-10-02 | 2014-04-03 | Intermune, Inc. | Anti-fibrotic pyridinones |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| WO2014125408A2 (en) | 2013-02-12 | 2014-08-21 | Aurigene Discovery Technologies Limited | Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors |
| BR112015022674A2 (pt) * | 2013-03-11 | 2017-07-18 | Abbvie Inc | inibidores de bromodomínio |
| WO2014139324A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Tetracyclic bromodomain inhibitors |
| CN104211639A (zh) | 2013-06-05 | 2014-12-17 | 中国科学院上海药物研究所 | 一类炔基杂环类化合物及其应用 |
| US9688671B2 (en) | 2013-06-12 | 2017-06-27 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| JP2016525503A (ja) | 2013-06-28 | 2016-08-25 | アッヴィ・インコーポレイテッド | ブロモドメイン阻害剤 |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| WO2015081280A1 (en) | 2013-11-26 | 2015-06-04 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution |
| WO2015081246A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| EA034972B1 (ru) | 2014-04-23 | 2020-04-13 | Инсайт Корпорейшн | 1h-пирроло[2,3-c]пиридин-7(6h)-оны в качестве ингибиторов белков bet |
| WO2016055028A1 (en) * | 2014-10-10 | 2016-04-14 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| WO2016077375A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Bromodomain inhibitors and uses thereof |
| MA40940A (fr) * | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| US9763922B2 (en) | 2014-11-27 | 2017-09-19 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| CA2973597A1 (en) | 2015-01-23 | 2016-07-28 | Confluence Life Sciences, Inc. | Heterocyclic itk inhibitors for treating inflammation and cancer |
| EP3250571B1 (en) | 2015-01-29 | 2022-11-30 | Genentech, Inc. | Therapeutic compounds and uses thereof |
-
2015
- 2015-11-10 WO PCT/US2015/059997 patent/WO2016077375A1/en not_active Ceased
- 2015-11-10 CN CN201580072351.6A patent/CN107108613B/zh not_active Expired - Fee Related
- 2015-11-10 JP JP2017525079A patent/JP6639497B2/ja not_active Expired - Fee Related
- 2015-11-10 EP EP15801563.6A patent/EP3218376B1/en active Active
-
2017
- 2017-05-10 US US15/592,012 patent/US10258603B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107108613B (zh) | 2020-02-25 |
| HK1243072A1 (zh) | 2018-07-06 |
| US10258603B2 (en) | 2019-04-16 |
| EP3218376B1 (en) | 2019-12-25 |
| EP3218376A1 (en) | 2017-09-20 |
| CN107108613A (zh) | 2017-08-29 |
| US20170340604A1 (en) | 2017-11-30 |
| JP2017533250A (ja) | 2017-11-09 |
| WO2016077375A1 (en) | 2016-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6639497B2 (ja) | ブロモドメインインヒビターおよびその使用 | |
| JP6669745B2 (ja) | ブロモドメインのインヒビターとしての置換ピロロピリジン | |
| JP6636031B2 (ja) | 治療用化合物およびその使用 | |
| JP6669744B2 (ja) | ブロモドメインのインヒビターとしての置換ピロロピリジン | |
| JP6847844B2 (ja) | 治療用ピリダジン化合物およびその使用 | |
| JP6767969B2 (ja) | がんの処置における使用のためのｐｃａｆおよびｇｃｎ５阻害剤としての式（ｉ）のフタラジン誘導体 | |
| US10358437B2 (en) | Therapeutic compounds and uses thereof | |
| JP6659703B2 (ja) | ピリダジノン誘導体および癌の処置におけるそれらの使用 | |
| JP6709792B2 (ja) | 治療用化合物およびその使用 | |
| HK40079390A (en) | Substituted pyrrolopyrdines as inhibitors of bromodomain | |
| HK1243072B (zh) | 布羅莫結構域抑制劑及其用途 | |
| HK1242696A1 (en) | Therapeutic compounds and uses thereof | |
| HK1247193A1 (en) | Pyridazinone derivatives and their use in the treatment of cancer | |
| HK1242696B (zh) | 治療性化合物及其用途 | |
| HK1244282A1 (en) | Substituted pyrrolopyrdines as inhibitors of bromodomain | |
| HK1242695B (zh) | 作為用於治療癌症的pcaf和gcn5抑制劑的式(i)的酞嗪衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181108 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181108 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190722 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190718 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191021 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191101 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191128 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191224 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6639497 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |